ClinicalTrials.gov
Cure8 trial brief
Dapagliflozin in Patients With Ulcerative Colitis
Research and clinical trials
Mesalamine
Aminosalicylates
Phase 2 clinical trial
Clinicians
Researchers
Adult patients
Patients On Biologics
Why This Matters
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a new therapeutic approach, but the registry entry does not present results.
Who Should Pay Attention
Clinicians and researchers focused on IBD drug development or repurposing; adult patients with mild–moderate UC interested in clinical-trial developments.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2, Phase 3
Enrollment60 participants
Study statusCompleted
Source depthTrial registry record
What To Know
This is a completed interventional Phase 2/3 study (NCT05986136) conducted at Mansoura University in Egypt. Planned enrollment was 60 patients randomized to mesalamine alone (1 g three times daily) versus mesalamine plus dapagliflozin 10 mg once daily for 6 months.
The trial’s primary endpoint is change in the Mayo score, which incorporates endoscopy, bleeding, stool frequency, and physician assessment. The registry lists typical trial exclusion criteria such as current systemic steroids, immunosuppressives or biologics, severe UC, significant liver/kidney dysfunction, and pregnancy/breastfeeding.
The record does not report results or safety findings in the provided text.
Keep In Mind
This is a ClinicalTrials.gov record describing study design and eligibility; the provided text does not include trial results, safety data, or peer-reviewed publication. Dapagliflozin is primarily approved for diabetes and heart failure; its use in UC here is investigational.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorMostafa Bahaa
Trial IDNCT05986136
Study typeInterventional
Trial phasePhase 2, Phase 3
Enrollment60 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 21, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
Treatment of UC With Novel Therapeutics
This trial is testing a new experimental oral therapy (BRS201) aimed at reducing hydrogen sulfide–related metabolites in people with mild ulcerative colitis. If successful, the drug could represent a novel, non-biologic...
Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.